<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>A prospective double blind controlled trial was undertaken to examine the role of <z:chebi fb="1" ids="6909">metronidazole</z:chebi> as an adjunct to <z:chebi fb="0" ids="50858">corticosteroids</z:chebi> in the management of severe <z:hpo ids='HP_0100279'>ulcerative colitis</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>Thirty nine patients with severe <z:hpo ids='HP_0100279'>ulcerative colitis</z:hpo> were randomised on admission to hospital to receive either intravenous <z:chebi fb="1" ids="6909">metronidazole</z:chebi> 500 mg eight hourly (19 patients) or an identical intravenous placebo (20 patients) </plain></SENT>
<SENT sid="2" pm="."><plain>The two groups were similar with respect to age, sex, and the extent of <z:hpo ids='HP_0002583'>colitis</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>In addition <z:hpo ids='HP_0000001'>all</z:hpo> patients received a standard intravenous regimen consisting of <z:chebi fb="36" ids="29309">methyl</z:chebi> <z:chebi fb="2" ids="8378">prednisolone</z:chebi> 16 mg six hourly and parenteral nutrition together with a twice daily <z:chebi fb="2" ids="17650">hydrocortisone</z:chebi> 100 mg enema </plain></SENT>
<SENT sid="4" pm="."><plain>Treatment was continued for five days when the patients were formally assessed </plain></SENT>
<SENT sid="5" pm="."><plain>Fourteen of 19 patients (74%) receiving <z:chebi fb="1" ids="6909">metronidazole</z:chebi> and 14/20 (70%) receiving placebo were substantially improved, or in remission at the end of five days </plain></SENT>
<SENT sid="6" pm="."><plain>Five patients treated with <z:chebi fb="1" ids="6909">metronidazole</z:chebi> and six with placebo had no improvement and <z:hpo ids='HP_0000001'>all</z:hpo> proceeded to urgent colectomy with no operative mortality </plain></SENT>
<SENT sid="7" pm="."><plain>There were three late <z:hpo ids='HP_0011420'>deaths</z:hpo>, one in the <z:chebi fb="1" ids="6909">metronidazole</z:chebi> and two in the placebo group </plain></SENT>
<SENT sid="8" pm="."><plain>These results do not support the routine use of intravenous <z:chebi fb="1" ids="6909">metronidazole</z:chebi> in the treatment of severe <z:hpo ids='HP_0100279'>ulcerative colitis</z:hpo> </plain></SENT>
</text></document>